Wei Wang

Title: Innovations of Wei Wang in Sigma-1-Selective Ligands

Introduction

Wei Wang is an accomplished inventor based in Greenfield, Indiana. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target sigma-1 receptors. His work has implications for imaging and therapeutic applications in various medical fields.

Latest Patents

Wei Wang holds a patent for "Compounds comprising 4-benzoylpiperidine as a sigma-1-selective ligand." This patent describes bipiperidinyl compounds and their salts, which include high-affinity ligands for sigma receptors. Notably, some of these compounds exhibit high selectivity for sigma-1 receptors compared to sigma-2 receptors. The compounds can also incorporate radioisotopes, such as fluorine or carbon. Radiolabeled compounds developed from this patent can be utilized as probes for imaging the distribution of sigma-1 receptors in subjects, including humans, through positron emission tomography (PET) scanning.

Career Highlights

Wei Wang is affiliated with Washington University, where he continues to advance his research in the field of medicinal chemistry. His innovative work has garnered attention and recognition within the scientific community.

Collaborations

Wei Wang has collaborated with notable colleagues, including Zhude Tu and Robert H Mach. Their combined expertise contributes to the advancement of research in sigma receptor-targeted compounds.

Conclusion

Wei Wang's contributions to the field of medicinal chemistry, particularly through his patent on sigma-1-selective ligands, highlight his role as an innovative inventor. His work not only enhances our understanding of sigma receptors but also paves the way for future advancements in medical imaging and therapy.